ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 74.29 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $22.681 million which beat the analyst consensus estimate of $22.230 million by 2.03 percent. This is a 184.47 percent increase over sales of $7.973 million the same period last year.